STOCK TITAN
  1. Home
  2. News
  3. AGNPF

Algernon Pharmaceuticals Inc - AGNPF STOCK NEWS

Welcome to our dedicated news page for Algernon Pharmaceuticals (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Algernon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Algernon Pharmaceuticals's position in the market.

News
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (AGN) has signed a Letter of Intent with Seyltx Inc. to acquire Algernon’s NP-120 research program for USD $2M cash and a 20% common share equity position in Seyltx. The transaction is subject to certain conditions including Seyltx financing and the negotiation and execution of a definitive agreement, expected within the next 90 days. Algernon's Phase 2a study of idiopathic pulmonary fibrosis and chronic cough showed a significant reduction in cough count, leading to the decision to advance to a Phase 2b cough study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.47%
Tags
acquisition
-
News
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (AGN) Receives Japanese Patent for Repirinast to Treat NASH, CKD, and NAFLD, Valid Through 2038. The company's lead candidate shows promising results in reducing fibrosis and is a strong candidate for both indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
none
-
News
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
Rhea-AI Summary
Algernon Pharmaceuticals receives patent for CKD program drug NP-251 (Repirinast), positive data from NASH model, global IP suite expands
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
none
News
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Rhea-AI Summary
Algernon Pharmaceuticals Inc. announces completion of feasibility study and finalization of clinical trial design for Phase 2 DMT Stroke study. The study will investigate the use of DMT for the treatment of stroke and its ability to promote neuroplasticity in brain injuries. The decision to investigate DMT for stroke treatment was based on a ground-breaking rat occlusion stroke study that showed DMT reduced infarct volume and led to full recovery of motor function. The Phase 2 study will focus on safety and measures of efficacy including preservation of brain tissue, motor recovery, depression, and biomarkers linked to stroke pathophysiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.67%
Tags
clinical trial
-
News
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
Rhea-AI Summary
Algernon Pharmaceuticals announces non-brokered private placement for gross proceeds of CDN$205,000. Each unit consists of one common share and one common share purchase warrant. The offering is expected to close on July 21, 2023. The company will use the proceeds for working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
clinical trial
News
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.9%
Tags
conferences clinical trial
-
News
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
Rhea-AI Summary
Algernon Pharmaceuticals' subsidiary, Algernon NeuroScience, has completed dosing of the third and final cohort in its Phase 1 study of an intravenous formulation of AP-188 (DMT). The highest dose maintained plasma DMT concentrations at targeted levels without safety issues. The company plans to publish the data and move on to a Phase 2 study for stroke and traumatic brain injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
clinical trial
-
News
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
none
News
Algernon Pharmaceuticals Announces Closing of Rights Offering
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock AGNPF logo
Algernon Pharmaceuticals Inc

OTC:AGNPF

AGNPF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

AGNPF Stock Data

1.57M
14.89M
1.64%
13.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver